| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.fabinolife.com | |
| Market Cap | 5.84 Cr. | |
| Enterprise Value(EV) | 6.32 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 0.05 | Trailing Twelve Months Ending 2023-03 |
| Price-Earning Ratio (PE) | 540.56 | Trailing Twelve Months Ending 2023-03 |
| Industry PE | 38.73 | Trailing Twelve Months Ending 2023-03 |
| Book Value / Share | 19.59 | Trailing Twelve Months Ending 2023-03 |
| Price to Book Value | 1.42 | Calculated using Price: 27.80 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 0.21 Cr. | 2,100,000 Shares |
| FaceValue | 10 | |
| About Fabino Life Sciences Ltd. | ||
| The company is engaged in manufacturing, marketing, trading and packing of pharmaceutical and other wellness focused consumer products. The company's core business is marketing of pharmaceutical formulation & products in domestic market through own distribution network and sales force under own brand name, getting its ayurvedic formulations manufactured through loan licensing facilities, packing, labeling etc. | ||
| 1 Day |
|
-3.78% |
| 1 Week |
|
-3.78% |
| 1 Month |
|
-3.78% |
| 3 Month |
|
-10.23% |
| 6 Month |
|
-16.14% |
| 1 Year |
|
-11.57% |
| 2 Year |
|
|
| 5 Year |
|
|
| 10 Year |
|
| 5 years | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | 0.02 | 10.80 | 3.05 | 1.74 | 0.26 | |
| Return on Capital Employed (%) | 9.44 | 12.36 | 2.92 | 2.48 | 0.58 | |
| Return on Assets (%) | 0.00 | 1.14 | 1.04 | 1.37 | 0.22 |
| Particulars | 6 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 1 | 1 | 1 | 4 | 4 | 4 | |
| Non Curr. Liab. | 0 | 1 | 0 | 0 | 0 | 1 | |
| Curr. Liab. | 8 | 2 | 1 | 0 | 0 | 1 | |
| Minority Int. | |||||||
| Equity & Liab. | 9 | 4 | 2 | 5 | 5 | 5 | |
| Non Curr. Assets | 1 | 1 | 0 | 0 | 0 | 0 | |
| Curr. Assets | 8 | 3 | 2 | 4 | 5 | 5 | |
| Misc. Exp. not W/O | |||||||
| Total Assets | 9 | 4 | 2 | 5 | 5 | 5 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Net Sales | 3 | 8 | 3 | 4 | 3 | |
| Other Income | 0 | 0 | ||||
| Total Income | 3 | 8 | 3 | 4 | 3 | |
| Total Expenditure | -2 | -7 | -3 | -4 | -3 | |
| PBIDT | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 0 | 0 | 0 | 0 | 0 | |
| Taxation | 0 | 0 | 0 | |||
| Exceptional Items | ||||||
| PAT | 0 | 0 | 0 | 0 | ||
| Adjusted EPS | 5 | 0 | 0 | 0 |
| Particulars | 5 years | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 0 | 2 | 0 | -2 | -1 | |
| Cash Fr. Inv. | 0 | 0 | 0 | 0 | ||
| Cash Fr. Finan. | 0 | -2 | 0 | 2 | 0 | |
| Net Change | 0 | 0 | 1 | 0 | ||
| Cash & Cash Eqvt | 0 | 0 | 0 | 1 | 0 |
|
Mon, 13 Nov 2023
Board Meeting Outcome for Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2023 In continuation of our letter dated November 02 2023 and November 10 2023 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors the Company at their meeting held today i.e. November 13 2023 at Registered Office of the Company inter alia considered and approved the following;1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow.2. The Unaudited Consolidated Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow. |
|
Mon, 13 Nov 2023
Outcome Of Board Meeting & Submission Of Unaudited Financial Results For Half Year Ended September 30 2023 Outcome of Financial results for the Half-yearly ended September 2023 |
|
Fri, 10 Nov 2023
Board Meeting Intimation for Intimation About Adjournment Of Board Meeting Pursuant To Regulation 29 Of SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015 Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2023 inter alia to consider and approve In continuation of our letter dated November 02 2023 pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 it was intimated that the meeting scheduled to be held on November 10th 2023 now stands adjourned due to non-availability of Directors and the Chairman with the consent of all the directors/members present at the meeting hereby decided to adjourn the Meeting on November 13 2023 |
|
No Scans Found |
Equities
M.F.
Sectors
StockEdge Social